Pharvaris To Present Oral And Poster Data On Oral Deucrictibant At EAACI Annual Congress 2026

Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and lowers the price target from $75 to $74.

Pharvaris Q1 EPS $(0.69) Beats $(0.77) Estimate

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.77) by 10.39 percent. This is a 22.47 percent increase over losses of $(0.89) per share from the

Pharvaris Prices Underwritten Offering Of 3,874,664 Shares At $29.68 Per Share

All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 581,199 ordinary shares at the public offering price, less

Pharvaris Presents Data Evaluating Safety Margins Of Administration Of Deucrictibant IR Capsule In Combination With Deucrictibant XR Tablet At CIIC Spring 2026 Conference

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary

Wolfe Research Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $42

Wolfe Research analyst Andy Chen initiates coverage on Pharvaris (NASDAQ:PHVS) with a Outperform rating and announces Price Target of $42.

Wedbush Maintains Outperform on Pharvaris, Raises Price Target to $42

Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $41 to $42.

Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder

Pharvaris enrolled deucrictibant XR for HAE in CHAPTER 3. Positive results could lend 30% upside to the stock, says Guggenheim analyst.

RBC Capital Maintains Outperform on Pharvaris, Lowers Price Target to $51

RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and lowers the price target from $52 to $51.

Earnings Scheduled For April 2, 2026